Events Immune Response RNA 
Drug Target Review
JANUARY 2, 2024
In research published in Scientific Reports , 1 investigators focused on mesenchymal stem cells (MSCs), known for their potential in treating cell defects and regulating immune responses. In the lab, they labelled RNA molecules with fluorescent markers, enabling them to easily locate them within individual cells.
Broad Institute
JULY 11, 2024
Treatment with mIDH1 blockers unearths these remnants, triggering an immune response against the tumor cells. IDH1 normally facilitates the activity of enzymes called demethylases, which remove chemical flags called methylation marks from DNA, allowing genes to be transcribed into RNA.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
DECEMBER 14, 2020
Supported by promising phase 1 data, CureVac announced Monday that it has enrolled the first participant in the pivotal phase 2b/3 study of its messenger-RNA based coronavirus vaccine, CVnCoV. The company announced positive phase 1 trial results in November that demonstrated its candidate elicited immune responses and was well-tolerated.
The Pharma Data
DECEMBER 3, 2020
No serious adverse events related to the vaccine candidates studied were reported. The majority of adverse events were mild and transient. Strong Th1 cell-mediated immune responses were also observed for the vaccine candidates with either adjuvant.
The Pharma Data
SEPTEMBER 30, 2021
Anderson Professor of Chemical and Biomolecular Engineering, and his colleagues, are reporting in iScience the event of an intranasal subunit vaccine that gives durable local immunity against inhaled pathogens. A fundamental limitation of intramuscular vaccines is that they’re not designed to elicit mucosal immunity.
The Pharma Data
JANUARY 31, 2021
Adjuvanted S-Trimer COVID-19 vaccine candidates demonstrated favorable safety and tolerability profiles and strong neutralizing immune responses in a phase 1 trial. No serious adverse events related to the vaccine candidates studied were reported. CHENGDU, China , Feb.
Dark Matter Blog
JULY 16, 2021
As soon as I learned about DNA and RNA, I wanted to be a molecular biologist. Last stops at RNA My last roles in biotech were where my original passion began: DNA and RNA. My last stop at Arrakis Therapeutics is with a company targeting RNA with small molecules. I wanted to use molecular biology to create drugs.
Expert insights. Personalized for you.
128 
Let's personalize your content